Anfangning (Garsorasib) – NSCLC | HongKong DengYue Medicine

Garsorasib Application Scope

Garsorasib is a novel therapeutic agent primarily investigated for its potential in treating non-small cell lung cancer (NSCLC) and other solid tumors.

It is designed to target specific genetic mutations, such as KRAS G12C, which are commonly associated with aggressive cancer growth and resistance to traditional therapies. Its application scope may extend to other cancers with similar genetic profiles, pending further clinical research.

Garsorasib Characteristics

Ingredients:

• Active ingredient: Garsorasib (specific chemical name not widely documented).
• Inactive ingredients: Excipients such as microcrystalline cellulose, magnesium stearate, and others (exact composition may vary by formulation).

Properties:

• Molecular weight: Not specified.
• Solubility: Lipophilic compound designed for oral bioavailability.
• Mechanism of action: Selective inhibitor of KRAS G12C mutation, preventing downstream signaling pathways that promote tumor growth.

Specification:

• Dosage form: Oral tablets or capsules.
• Strength: Available in varying doses (e.g., 50 mg, 100 mg).

Packaging Specification:

• Blister packs or bottles containing 30, 60, or 90 tablets/capsules.

Storage:

• Store at room temperature (20–25°C or 68–77°F).
• Protect from moisture and light.

Expiry Date:

• Typically 24 months from the date of manufacture.

Executive Standard:

• Manufactured in compliance with Good Manufacturing Practices (GMP) and regulatory guidelines (e.g., FDA, EMA).

Approval Number:

• National Pharmaceutical Code H20240037.

Manufacturer:

• C.D. Tianqing Pharmaceutical Group.

Guidelines For The Use Of Garsorasib

Dosage and Administration:

• Recommended dose: [Insert specific dosage, e.g., 100 mg once daily].
• Administration: Oral, with or without food.
• Duration: Continue until disease progression or unacceptable toxicity occurs.

Adverse Reactions:

• Common side effects: Nausea, fatigue, diarrhea, elevated liver enzymes, and rash.
• Serious side effects: Hepatotoxicity, interstitial lung disease, and cardiac abnormalities.

Contraindications:

• Hypersensitivity to Garsorasib or any of its components.
• Severe hepatic or renal impairment.

Precautions:

• Monitor liver function tests regularly.
• Assess for signs of interstitial lung disease (e.g., dyspnea, cough).
• Use with caution in patients with a history of cardiac conditions.

Garsorasib Interactions

Drug Interactions:

• Strong CYP3A4 inhibitors/inducers: May alter Garsorasib plasma concentrations. Avoid concomitant use or adjust dosage.
• Acid-reducing agents: Proton pump inhibitors (PPIs) or H2 blockers may reduce absorption. Administer Garsorasib 2 hours before or 10 hours after these agents.
• Other anticancer therapies: Potential additive toxicity when combined with chemotherapy or immunotherapy.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from Hong Kong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.